妇康片治疗子宫内膜单纯性增生的临床分析

目的观察子宫内膜单纯性增生患者服用妇康片前后子宫内膜雌激素受体(estrogen receptor,ER)、孕激素受体(progesterone receptor,PR)与增殖细胞核抗原(proliferative cell nuclear antigen,PCNA)表达的变化,为临床治疗提供理论依据。方法病理诊断子宫内膜单纯性增生患者30例,分段诊刮术后第5天及下两次月经周期第5天开始口服妇康片,5mg/d,连服22d,共3个月经周期,于第3个月经周期的第25~28天取子宫内膜组织。用免疫组织化学染色法观察治疗前后雌激素受体、孕激素受体、增殖细胞核抗原的表达变化。结果口服妇康片治疗3个月经周期后,患者月经周期缩短,经量减少。子宫内膜单纯性增生治疗前ER、PR与PCNA的表达分别为3.33±1.92、4.13±1.55和4.40±1.54,经口服妇康片治疗3个周期后ER、PR和PCNA的表达分别为1.97±1.87、1.80±1.75和1.83±1.00。与治疗前ER、PR和PCNA的表达比较,差异有统计学意义(P<0.05)。结论妇康片可抑制子宫内膜细胞增殖活性,降低ER、PR和PCNA表达,可有效治疗子宫内膜单纯性增生。

Clinical Analysis of the Therapeutic Effects of Norethindrone on Simple Endometrial Hyperplasia

Objective To study the effects of Norethindrone on biological features of estrogen receptor(ER), progesterone receptor(PR)and proliferative cell nuclear antigen(PCNA) in patients with simple endometrial hyperplasia(EH).Methods Thirty cases diagnosed by curettage and pathological examination were given Norethindrone 5 mg everyday for 22 days from the 5 day after curettage and 5th days from onset of second and third mentrual periods. The pathology of endometrium was examined at the 25～28 days of the third periad. ER, PR, PCNA expressions were examined with immunohistochemical methods pre-and after-treament by Norethindrone for 3 monthes.Results After three periods of treatment by Norethindrone, the menstrual durations were shortened obviously, the amount of flow and clots were decreased. The expressions of ER, PR and PCNA in simple endometrial hyperplasia before treatment were 3.33±1.92, 4.13±1.55 and 4.40±1.54 respectively. After three periods of treatment, expressions of ER, PR and PCNA were 1.97±1.87, 1.80±1.75 and 1.83±1.00 respectively, which were significantly lower than those of the pretreatment ones(P<0.05).Conclusion Norethindrone is effective in the treatment of simple endometrial hyperplasia.